Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding

alkiviadis.1961 shared this article with you from Inoreader Analysis of Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding: A Retrospective Study Via Latest Results for Journal of Gastrointestinal Surgery Abstract Background No reliable method has been reported for determining tumor budding with frozen sections during surgical procedures. This study investigated endoscopic features predictive of tumor budding in early gastric cancers (EGC). Methods This retrospective study evaluated data from 137 patients diagnosed with EGC who underwent endoscopy, followed by endoscopic submucosal dissection (ESD); 71 patients underwent a second gastrectomy. Based on pathological analyses, lesions were categorized as being positive (n = 80) or negative for tumor budding (n = 57). Endoscopic features were analyzed using multivariable logistic regression. Patient survival rates were analyzed with Kaplan–Meier method and log-rank test. Results Mean age of our study population was 66 years (range, 31–86 years). The tumor budding-positive cohort (73.3 ± 5.9 years) was significantly older than the tumor budding-negative cohort (56.7 ± 7.6 years) (p < 0.001). Endoscopic features significantly different between tumor budding-positive and budding-negative groups included tumor size (p = 0.003), remarkable redness (p = 0.015), and margin elevation (p < 0.001). Tumor size (odds ratio (OR): 1.561; 95% confidence interval (CI): 0.984, 2.285; p = 0.047) and margin elevation (OR: 2.141; 95% CI: 1.147, 5.117; p = 0.003) were independent predictors of tumor budding. Margin elevation was found in 19.3% of tumor budding-negative and 53.8% of budding-positive cases. In the tumor budding-positive group, ESD and second gastrectomy were associated with disease-free survival. Conclusions Margin elevation and large tumor size (> 29 mm) of EGCs on endoscopy are promising imaging biomarkers for predicting tumor budding in EGCs. ESD and a second gastrectomy can be better for tumor budding-positive patients with EGCs. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.